Ex vivo translational studies employing a perfusion bioreactor for tissue engineering to model the tumor microenvironment of freshly excised human breast cancer biopsies evinced therapeutic effects of anti-estrogens, pertuzumab and checkpoint inhibitors on ER+HER2+ tumor cells [13]. This evidence concerns the gene ERBB2 and breast carcinoma.